What Artia Global Partners LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1937964 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 589.1K |
| −6.3% |
| $62.8M |
| 11.6% |
TRVITrevi Therapeutics, Inc. | 2.2M | +9.8% | $41.2M | 7.6% |
BTSGBrightSpring Health Services, Inc. | 517.3K | +861.6% | $36.1M | 6.7% |
RVMDRevolution Medicines, Inc. | 185.4K | +48.3% | $34.7M | 6.4% |
ARGXArgenx SE | 29.7K | ±0% | $27.6M | 5.1% |
ALKSAlkermes plc. | 449K | New | $23.5M | 4.3% |
TVTXTravere Therapeutics, Inc. | 339K | +379.5% | $19.3M | 3.6% |
AZNAstraZeneca PLC | 98.4K | +3.1% | $18.7M | 3.4% |
NAMSNewAmsterdam Pharma Co N.V. | 503.9K | ±0% | $17.1M | 3.2% |
DNTHDianthus Therapeutics, Inc. | 163K | ±0% | $15.9M | 2.9% |
SPDR SERIES TRUSTST STR SP BIOTPut option | 100K | New | $15.8M | 2.9% |
DGXQuest Diagnostics Inc | 65.1K | +59.5% | $13.8M | 2.5% |
IONSIonis Pharmaceuticals Inc | 144.4K | ±0% | $11.4M | 2.1% |
EYPTEyePoint, Inc. | 767.1K | ±0% | $11M | 2% |
ALMSAlumis Inc. | 278.5K | −14.3% | $7.8M | 1.4% |
VKTXViking Therapeutics, Inc. | 180.7K | ±0% | $7.1M | 1.3% |
CELCCelcuity Inc. | 59.3K | +280.8% | $6.2M | 1.1% |
CYTKCytokinetics Inc | 70.7K | +333.7% | $6M | 1.1% |
MRKMerck & Co., Inc. | 46.7K | ±0% | $6M | 1.1% |
RAPPRapport Therapeutics, Inc. | 138.5K | ±0% | $5.8M | 1.1% |
JNJJohnson & Johnson | 22.6K | ±0% | $5.7M | 1.1% |
GHGuardant Health, Inc. | 38.1K | New | $5.7M | 1.1% |
ABSIAbsci Corp | 464.4K | New | $5.4M | 1% |
SRRKScholar Rock Holding Corp | 96.3K | ±0% | $5.3M | 1% |
SIONSionna Therapeutics, Inc. | 119.7K | ±0% | $5.3M | 1% |
ASNDAscendis Pharma A/S | 17.7K | New | $4.7M | 0.9% |
ROIVRoivant Sciences Ltd. | 129.8K | ±0% | $4.6M | 0.8% |
PALIPalisade Bio, Inc. | 2M | ±0% | $4.2M | 0.8% |
EWTXEdgewise Therapeutics, Inc. | 98.8K | +50.8% | $4M | 0.7% |
BIIBBiogen Inc. | 18.4K | ±0% | $4M | 0.7% |
XENEXenon Pharmaceuticals Inc. | 65K | ±0% | $3.9M | 0.7% |
BLTEBelite Bio, Inc | 25K | ±0% | $3.8M | 0.7% |
MLYSMineralys Therapeutics, Inc. | 137.8K | ±0% | $3.7M | 0.7% |
PROKProkidney Corp. | 1.8M | ±0% | $3.7M | 0.7% |
ELVNEnliven Therapeutics, Inc. | 72.1K | +245.0% | $3.7M | 0.7% |
ORKAOruka Therapeutics, Inc. | 33.4K | New | $3.2M | 0.6% |
PTGXProtagonist Therapeutics, Inc | 23K | +0.1% | $2.8M | 0.5% |
UTHRUNITED THERAPEUTICS Corp | 5K | ±0% | $2.7M | 0.5% |
DRUGBright Minds Biosciences Inc. | 38.4K | ±0% | $2.7M | 0.5% |
KNSAKiniksa Pharmaceuticals International, plc | 29.2K | ±0% | $1.9M | 0.3% |
CMPXCompass Therapeutics, Inc. | 383.2K | New | $839.2K | 0.2% |
PRAXPraxis Precision Medicines, Inc. | 2.5K | ±0% | $837K | 0.2% |
KODKodiak Sciences Inc. | 17K | ±0% | $663.1K | 0.1% |
TENXTenax Therapeutics, Inc. | 42.1K | ±0% | $612.3K | 0.1% |
NUVLNuvalent, Inc. | 4.9K | ±0% | $605.2K | 0.1% |
PEPGPepGen Inc. | 205.3K | ±0% | $369.6K | 0.1% |
SYRESpyre Therapeutics, Inc. | 4K | New | $355.1K | 0.1% |
